theatlantic | Doctors aren’t entirely sure what triggers rheumatoid arthritis, a
disease in which the body turns on itself to attack the joints, but an
emerging body of research is focusing on a potential culprit: the
bacteria that live in our intestines.
Several recent studies have found intriguing links between gut
microbes, rheumatoid arthritis, and other diseases in which the body’s
immune system goes awry and attacks its own tissue.
A study
published in 2013 by Jose Scher, a rheumatologist at New York
University, found that people with rheumatoid arthritis were much more
likely to have a bug called Prevotella copri in their intestines than people that did not have the disease. In another study
published in October, Scher found that patients with psoriatic
arthritis, another kind of autoimmune joint disease, had significantly
lower levels of other types of intestinal bacteria.
This work is part of a growing effort by researchers around the world
to understand how the microbiome—the mass of microbes that live in the
gastrointestinal tract—affects our overall health. The gut contains up
to a thousand different bacteria species, which together weigh between
one and three pounds. This mass contains trillions of cells, more than
the number of cells that make up our own bodies. Over the past several
years, scientists have compiled a growing collection of evidence that
many of these bugs may have a major effect on our well-being, with some
triggering chronic, non-infectious ailments such as rheumatoid
arthritis, and others protecting against such diseases.
“It’s become more and more clear that these microbes can affect the
immune system, even in diseases that are not in the gut,” says Veena
Taneja, an immunologist at the Mayo Clinic in Rochester, Minnesota, who
has found clear differences in the bacterial populations of mice bred to
be genetically prone to rheumatoid arthritis. In those more susceptible
to the disease, a species of bacteria from the Clostridium family dominates. In mice without arthritis, other strains flourish, and the Clostridium strains are scarce.
“This is frontier stuff,” says Scher, the director of the NYU’s
Microbiome Center for Rheumatology and Autoimmunity. “This is a shift in
paradigm. By including the microbiome, we’ve added a new player to the
game.”
0 comments:
Post a Comment